© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Upadacitinib Shows Long-Term Efficacy in Adolescent Atopic Dermatitis: Daily Dose
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On December 11, 2024, we reported on findings from a study published in JAMA Dermatology that examined the long-term efficacy and safety of upadacitinib (Rinvoq; abbvie) in adolescents with moderate-to-severe atopic dermatitis (AD).
The study
Researchers assessed data from three phase 3 randomized clinical trials including 542 adolescents aged 12 to 17 years with moderate to severe AD.
In the Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318) trials, once-daily upadacitinib, 15 mg or 30 mg, adolescents were randomly assigned to receive once-daily upadacitinib 15 mg, 30 mg, or placebo alone (Measure Up 1 and Measure Up 2) or with topical corticosteroids (AD Up) through 76 weeks.
The findings
At week 76, Eczema Area and Severity Index Score (EASI-75) among participants who received upadacitinib 15 mg was achieved by 89.1%, 84.4%, and 87.8% in the Measure Up 1, Measure Up 2, and AD Up trials, respectively.
Among the 30 mg cohort in each trial, EASI-75 was achieved by 96.1%, 93.6%, and 82.7% of adolescents, with results having indicated maintenance or improvement in EASI-75 across 76 weeks, respectively.
Achievement of efficacy measured by Validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 and Worst Pruritus Numerical Rating Scale improvement of 4 points or more from baseline were either maintained or improved through 76 weeks of upadacitinib 15 mg or 30 mg treatment.
